Fighting Cancer with NanoTherm® therapy

MagForce has successfully moved forward on its path to develop NanoTherm® therapy into a valued treatment for brain and prostate cancer.
We have five NanoActivator® devices in operation in world-class German hospitals, and additional centers are trained to perform the instillation of the nanoparticles. Commercial treatments have now re started, and patients from all over the world can benefit from our unique technology. Additionally, in the US, we have filed the registration clinical trial with the FDA. We expect this trial will prove that NanoTherm® therapy can fulfill the desired outcome in the focal treatment of prostate cancer, avoiding surgery and other treatments with well-known side effects. We delivered and now we are continuing to successfully establish our technology for the benefit of patients in both Europe and the US.

Compliant with European Standard